New Report Tracks Medicaid Preferred Drug List Changes

SRWA's newest report, PDL Track©, is a cost-effective way for pharmaceutical companies to track formulary status of Medicaid products by PDL

DOWNINGTOWN, PA (PRWEB) March 29, 2004 --- S. R. Ware Associates, Inc. (SRWA) announces the publication of PDL Track©, a new and cost-effective report that follows the formulary status of Medicaid preferred drug list (PDL) products by state, type of program, therapeutic class and other data. PDL's are a "hot topic" between Medicaid and the pharmaceutical industry; therefore, every company needs to know what is happening with their products at the state level. SRWA has been providing cost-effective reports for small and big pharma since 1995.

We already publish a comprehensive report on PDL's, but many of our clients asked that we provide a simple report tracking the formulary status of their product on Medicaid," says Steve Ware, President of SRWA. Our new report, PDL Track©, captures PDL movements by states as they build and change preferred drug lists. Many states have considered or will implement some type of PDL program in 2003 and 2004."

PDL Track© is Unique
SRWA Reports: PDL Track© is published quarterly and has information on:
• Which states have PDLs
• What PDL has your product as preferred,
• Therapeutic categories, and
• Whether brands or generics are preferred.

SRWAs PDL Track© is important for both small and large pharmaceutical companies because it:
• Alerts field and office staff to therapeutic class changes, which is vital to long-term planning,
• Allows for the efficient use of knowledge and enhances communication and goal setting, and
• Is a cost effective and inexpensive first-class reference, unique to the industry.

Innovative Concepts are a Trademark of SRWA
This is an innovative concept," says Ware. Targeted reports such as our PDL Track© report can enhance the value of new and established products as well as the value of the team managing the process. Many pharma companies do not have the field or home office staff to cover every state. Thats where we provide the helping hand."

Additional SRWA Reports are due to be released in 2004 and will cover Medicaid managed care and other drug programs. Contact SRWA for more information and a sample of our report.

About The SRWA Report©: PDL Track©
The SRWA Report is available from S. R. Ware Associates, Inc. as a comprehensive report published annually. To find out more about SRWA concepts, cost, and delivery times, call 610-321-6191 or e-mail SRWA info@srwa.net

About S. R. Ware Associates, Inc.
S. R. Ware Associates, Inc. (SRWA) opened its doors in 1995 as a contract consultant group focused on pre- and post-launch pharmaceutical, biotechnology, or laboratory products requiring approval from Medicaid, Medicare, or other entities. The companys prime focus is on marketing and market research, but also conducts sales and management training. SRWA President and founder Steve Ware is a 25-year veteran of pharmaceutical sales, market research, knowledge management, and opinion leader development. SRWA draws upon a cadre of experienced associates with expertise in lobbying, sales management, advocacy, and a variety of therapeutic areas.

More information about SRWA is available by visiting http://www.srwa.net